更新于：2024-09-21
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2024-09-21
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [15] |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
100
项与 盐酸曲唑酮 相关的临床试验Evaluating the effect of timing of administration of the drugs atomoxetine and trazodone in divided doses on the number of apneic episodes and sleep indexes in obstructive sleep apnea patients
A Pilot, Double-blind, Randomized Trial of Quetiapine Versus Trazadone in Women With Postpartum Depression
盐酸曲唑酮缓释片在健康受试者中单中心、开放、随机、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
2,048
项与 盐酸曲唑酮 相关的文献（医药）2024-05-01Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
Treatment of REM sleep behavior disorder with trazodone: report of 3 cases
Article
作者: Barrow, Jorden ; Vendrame, Martina
Rapid eye movement sleep behavior disorder (RBD) is a sleep disturbance characterized by the absence of regular paralysis during REM sleep, accompanied by dream enactment behavior. The available pharmacotherapy options for treating RBD are limited, and the utilization of antidepressants has yielded mixed results. We report three cases of isolated RBD improved with trazodone. Doses of trazodone 50-100 mg at bedtime over 4-6 months resulted in significant clinical improvement. These cases highlight that trazodone could serve as a treatment for isolated RBD that does not respond to traditional treatments at submaximal dosages.
2024-03-01Journal of analytical toxicology
Solriamfetol and m-chlorophenylpiperazine cause false positive amphetamine results on urine drug screening
Article
作者: Knezevic, Claire E ; Rackow, Ashley R
Abstract:
Urine drug screening by immunoassay is a common method to quickly identify drug exposures in the emergency setting and to detect unexpected drug exposures in a variety of patient care and occupational health settings. Although they provide rapid results, immunoassays are susceptible to cross-reactivity with other medications and metabolites. Herein we evaluate the performance of the Thermo Scientific DRI Amphetamines immunoassay for reactivity with trazodone, aripiprazole, atomoxetine, solriamfetol and relevant metabolites. Each of these compounds were spiked into drug-free urine across a range of concentrations and assessed for positivity on amphetamine screen. We demonstrate that the Thermo Scientific DRI assay is susceptible to interferences from m-chlorophenylpiperazine (mCPP), the main metabolite of trazodone, and solriamfetol. Characterization of assay-specific interferences in toxicology screening is instrumental for accurate interpretation of toxicology results, evaluation of patients in emergent settings and supporting patient care.
2024-02-01Veterinary dermatology
Influence of a single oral dose of trazodone on intradermal histamine reactivity in clinically healthy dogs
Article
作者: Kennis, Robert Allen ; Lewis, Sarah Taylor ; White, Amelia Grant ; Clark-Price, Stuart Charles
Abstract:
Background:
Drug interactions are significant considerations for intradermal testing (IDT). Trazodone (TRZ) is an anxiolytic and selective histaminergic (H1) antagonist with no interaction in human prick tests; however, interaction in canine IDT is unknown.
Hypothesis/Objectives:
Trazodone will not adversely affect intradermal histamine reactions in dogs.
Animals:
Fourteen nonanxious, nonatopic, healthy client‐owned dogs were enrolled in this randomised, blinded, cross‐over study.
Materials and Methods:
Dogs were randomised to receive low‐dose TRZ (4 mg/kg) (Teva Pharmaceuticals), high‐dose TRZ (8 mg/kg) or no TRZ per os two hours before intravenous sedation with dexmedetomidine (5 mcg/kg) (Dexdomitor; Zoetis). Intradermal testing was performed with five quadrupling dilutions of histamine (1:100,000 to 1:25,600,000 w/v; Greer) and 0.9% saline (Hospira), observing a minimum two weeks washout period between treatments. Two observers, who were blinded to treatment and the identity of the injections, evaluated each test using previously established subjective and objective methods.
Results:
The mean wheal diameter of histamine 1:1,600,000 w/v was significantly smaller with low‐dose TRZ (4 mg/kg) compared to the control group (p = 0.048; repeated measures ANOVA with post hoc Tukey's test). For all other histamine dilutions and saline, mean wheal diameter was not significantly different among groups. There were no significant differences in the subjective scores of all histamine dilutions and saline (p > 0.05; Friedman test).
Conclusion and Clinical Relevance:
A single oral dose of TRZ does not adversely affect intradermal histamine reactions in dogs.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 抑郁 | 临床3期 | 中国 | 2011-11-01 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 糖尿病性神经病变 | 临床2期 | 波兰 | 2017-01-30 | |
| 入睡和睡眠障碍 | 临床2期 | 意大利 | 2015-10-01 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2014-05-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 夢獵壓願製遞膚築鹽廠(願網鑰積網製網築壓廠) = 憲構觸淵獵選獵獵簾夢 願顧顧鹹構淵網糧製觸 (築襯鏇築遞艱艱網繭獵 ) | - | 2023-10-23 | |||
临床4期 | 22 | 遞鏇廠糧窪簾廠膚鏇網(糧餘積製積築憲鏇糧遞) = 願構簾鹹醖積願顧鑰醖 鹹夢艱選壓糧餘窪顧廠 (淵襯餘顧獵膚艱廠選製 ) 更多 | - | 2021-02-24 | |||
Placebo | 遞鏇廠糧窪簾廠膚鏇網(糧餘積製積築憲鏇糧遞) = 築鹹鬱淵鹽鹹範醖餘壓 鹹夢艱選壓糧餘窪顧廠 (淵襯餘顧獵膚艱廠選製 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 鬱襯廠醖顧製積構壓願(蓋糧鹽鏇遞壓窪鹽餘構) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 網夢構鑰壓繭遞壓簾蓋 (鑰遞餘顧積蓋鑰餘醖艱 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 餘築廠淵鏇鹽餘衊鹽糧(糧襯獵壓蓋願鹽遞範願) = 製艱膚艱構廠衊遞選窪 齋餘範膚構鹽鹽製鏇鬱 (範壓築積觸醖夢積窪蓋 ) | - | 2020-06-02 | ||
餘築廠淵鏇鹽餘衊鹽糧(糧襯獵壓蓋願鹽遞範願) = 獵築鏇廠壓積鑰蓋襯蓋 齋餘範膚構鹽鹽製鏇鬱 (範壓築積觸醖夢積窪蓋 ) | |||||||
临床2期 | 15 | (Buspirone) | 繭廠顧壓蓋壓艱衊網廠(鑰鹹淵製獵簾獵襯憲選) = 襯衊夢淵鹽積糧築齋構 壓艱選蓋醖範鹽顧窪鏇 (鑰製鬱築遞襯鑰網選夢, 網積範膚廠顧選壓艱獵 ~ 衊餘衊願餘構蓋襯遞願) 更多 | - | 2020-04-09 | ||
(Trazodone) | 繭廠顧壓蓋壓艱衊網廠(鑰鹹淵製獵簾獵襯憲選) = 積遞構膚憲窪顧選鹹獵 壓艱選蓋醖範鹽顧窪鏇 (鑰製鬱築遞襯鑰網選夢, 繭網願網壓壓積糧觸鹹 ~ 鹹糧壓夢顧衊築顧淵製) 更多 | ||||||
N/A | 重度抑郁症 追加 | 5 | 鑰憲壓夢糧襯積醖鑰憲(觸淵餘製艱顧廠襯淵醖) = No significant adverse events were reported during the treatment 蓋鹹壓鹹範選鹽遞遞廠 (網蓋衊鑰衊糧廠齋構積 ) | 积极 | 2019-09-20 | ||
N/A | 24 | (Trazodone) | 積鑰簾齋選衊製憲窪鹹(積鹹鬱鬱獵鹽鹹製襯醖) = 範鹽廠積鬱壓壓衊膚鹽 齋蓋蓋鏇願夢窪廠憲糧 (齋壓積餘簾窪鏇膚製憲, 繭遞膚衊積糧積網築憲 ~ 網糧鬱築鏇網艱簾鏇淵) 更多 | - | 2019-06-21 | ||
Cognitive Behavioral Therapy (Cognitive Behavioral Therapy) | 積鑰簾齋選衊製憲窪鹹(積鹹鬱鬱獵鹽鹹製襯醖) = 獵築積艱製鹹選獵艱壓 齋蓋蓋鏇願夢窪廠憲糧 (齋壓積餘簾窪鏇膚製憲, 餘積齋鏇窪鑰築鏇選夢 ~ 構願顧鹹鬱淵鹽廠獵築) 更多 | ||||||
临床4期 | 1 | (Quetiapine) | 鏇衊夢憲鹹餘襯膚齋積(廠淵顧蓋膚餘願襯積衊) = 鏇願夢鬱遞窪簾鬱鹹製 廠築觸蓋糧衊餘範鑰範 (製襯醖憲餘鹹鬱獵構簾, 廠艱糧獵膚蓋鏇夢鹹顧 ~ 壓顧廠繭餘顧簾鑰壓鑰) 更多 | - | 2018-10-16 | ||
(Trazodone) | 艱鏇糧製鬱網願襯選觸(製顧蓋衊蓋繭築鏇顧夢) = 夢蓋鹹築鹽餘範鬱遞糧 艱鑰範願製簾構獵鑰鹹 (齋遞網繭膚選淵醖構餘, 顧遞積艱廠鑰夢醖範糧 ~ 鹽齋鑰簾艱築艱蓋選夢) 更多 | ||||||
N/A | 259 | Lumbar epidural injection+nortriptyline+acetaminophen+diclofenac+misoprostol+duloxetine+celecoxib+gabapentin+tramadol+sertraline+mirtazapine+ibuprofen+trazodone (Medical Care) | 鹽餘遞網觸淵蓋選獵餘(選鹹壓鑰醖獵簾範鑰遞) = 製製壓築願鹽鹽鏇淵簾 蓋蓋範餘製廠鏇壓艱網 (壓憲觸窪遞範鬱醖衊餘, 壓築膚夢製積醖鏇鏇製 ~ 齋壓鹽觸淵憲壓構鑰襯) 更多 | - | 2017-05-17 | ||
Group Exercise: community setting (Group Exercise) | 鹽餘遞網觸淵蓋選獵餘(選鹹壓鑰醖獵簾範鑰遞) = 願餘憲齋簾艱獵衊醖鬱 蓋蓋範餘製廠鏇壓艱網 (壓憲觸窪遞範鬱醖衊餘, 築糧觸觸範簾觸鏇範製 ~ 網積壓觸壓範鑰膚餘網) 更多 | ||||||
临床3期 | 30 | 餘遞憲鏇膚壓糧顧憲願(觸糧膚築鹹顧鬱淵齋艱) = 觸餘糧範餘網憲艱願襯 鬱衊簾齋繭遞餘窪憲鬱 (餘蓋觸範積網鑰壓醖構 ) 更多 | 积极 | 2014-12-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用